| Symbol | CYDX |
|---|---|
| Name | CYDUCT DIAGNOSTICS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 06880 United States CT 1698 Post Road E Suite 1A |
| Telephone | +1 888-545-9112 |
| Fax | — |
| — | |
| Website | http://www.CYductDX.com |
| Incorporation | US |
| Incorporated On | 2005 |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | TPS THAYER, LLC; |
| Audit Status | UNAUDITED |
| Reporting Status | Alternative Reporting Standard |
| CIK | 0001388994 |
| Description | CYduct Diagnostics, Inc., headquartered in Westport, Connecticut, develops, produces, and markets medical products for the assessment, identification, diagnosis and ultimately treatment of early-stage breast disease. CYduct will provide personalized risk assessment tools and help identify precancerous and cancerous lesions within the mammary ducts. The CYduct technology platforms will be single-use, proprietary, high-margin, high-volume suite of breast care products which assess, screen, detect, monitor and treat identifiable changes that distinguish variations in breast health. CYduct is committed to providing both women and clinicians with noninvasive and minimally invasive technology that will continue to accelerate the intraductal evolution and improvement in the ability to: 1) assess breast health risk, 2) monitor breast health, 3) identify the need for increased personalized risk surveillance and 4) provide the tools to monitor, diagnose/treat breast disease through visual examination (Breast Endoscopy) within the ductal system of the breast. Additional info from OTC: |
No news found.